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Background: Diabetes has been shown to be independent predictor of restenosis after percutaneous coronary
intervention (PCI). The aim of the present study was to investigate whether a pre- and post-procedural glycaemic
control in diabetic patients was related to major advance cardiovascular events (MACE) during follow up.
Methods: We evaluated 2884 consecutive patients including 2181 non-diabetic patients and 703 diabetics who
underwent coronary stenting. Diabetes mellitus was defined as the fasting blood sugar concentration ≥ 126 mg/dL,
or the use of an oral hypoglycemic agent or insulin at the time of admission. Diabetic patients were categorized
into two groups based on their mean HbA1c levels for three measurements (at 0, 1, and 6 months following
procedure): 291 (41.4%) diabetics with good glycaemic control (HbA1c≤ 7%) and 412 (58.6%) diabetics with poor
glycaemic control (HbA1c> 7%).
Results: The adjusted risk of MACE in diabetic patients with poor glycaemic control (HbA1c> 7%) was 2.1 times of
the risk in non-diabetics (adjusted HR = 2.1, 95% CI: 1.10 to 3.95, p= 0.02). However, the risk of MACE in diabetics
with good glycaemic control (HbA1c≤ 7%) was not significantly different from that of non-diabetics (adjusted
HR= 1.33, 95% CI: 0.38 to 4.68, p= 0.66).
Conclusions: Our data suggest that there is an association between good glycaemic control to obtain HbA1c
levels ≤7% (both pre-procedural glycaemic control and post-procedural) with a better clinical outcome after PCI.
Keywords: Diabetes mellitus, Percutaneous coronary intervention, Glycaemic control, Major adverse cardiovascular eventsBackground
Despite recent advances in medical management and
coronary revascularization, cardiovascular disease
accounts for about 75% of all hospital admissions and
80% of deaths in diabetic patients [1]. Although the
introduction of drug-eluting stents has reduced the rates
of restenosis and clinical events after percutaneous cor-
onary intervention (PCI), since the diabetes mellitus has
been proved to be a strong risk factor for in-stent
restenosis [2-4], restenosis after stent implantation* Correspondence: hami_nag@yahoo.com
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reproduction in any medium, provided the orremains the “Achilles’ heel” of PCI [5], and patients with
diabetes still have poorer clinical outcomes compared
with non-diabetics [6-10].
The higher rates of restenosis in diabetic patients might
be partly explained by exaggerated neointimal prolifera-
tion after stent implantation due to hyperinsulinemic state
of diabetes [11]. Glycosylated hemoglobin (HbA1c) is re-
flective of mean ambient fasting and postprandial plasma
glucose levels over the preceding 2 to 3 months [12, 13].
There is consistent evidence that optimal glycaemic con-
trol (defined as HbA1c≤ 7%) results in a lower incidence
of microvascular complications in both type 1 and type 2
diabetes mellitus [14]. However, the corollary that optimal
glycaemic control in diabetic patients would lead to a
similar improvement in clinical outcome of PCI has notl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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data regarding the effect of preprocedural glycaemic con-
trol on outcome of PCI, there is limited data about the im-
pact of post-procedural glycaemic control, beginning at
the time of PCI and continuing afterwards, on incidence
of MACEs after PCI.
In this study, we sought to investigate whether a pre-
and post-procedural glycaemic control in diabetic
patients, as reflected by mean plasma HbA1c levels prior
to and 1 and 6 months after elective coronary stenting,
was related to major advance cardiovascular events
(MACE) during 1-year follow up.
Methods
Study population
Between October 2007 and December 2009, all consecu-
tive patients scheduled for elective PCI at the cardiac
catheterization laboratory of our center were enrolled in
this prospective cohort study (Figure 1). During this
period angioplasty procedure were performed in 3964
patients. Patients requiring non-elective procedures for
acute coronary syndromes (n = 869), and patients who
refused to participate in the study (n = 102) were
excluded. The remaining 2993 patients were compatible
with our selection criteria. The study protocol wasAssessed for el
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Lost to follow-up (n=7)
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Figure 1 Flow diagram of patient recruitment and follow-up. HbA1c, gapproved by the ethics committee of Tehran University
of Medical Sciences. Written informed consents were
obtained from all participants.
Coronary procedures and adjunctive antiplatelet therapy
PCI and intracoronary stent implantation were per-
formed according to current guidelines and using stand-
ard percutaneous techniques. Choosing the type of stent
was at the discretion of the operator and each operator
relied on his own judgment to assess stent expansion.
All patients were on aspirin and received a 5,000–10,000
unit bolus unfractionated heparin in order to achieve an
activated clotting time >250 sec. Patients also received
300–600 mg oral clopidogrel initiated either before or in
the catheterization laboratory at the discretion of the op-
erator, and continued at the dose of 75 mg/day for at
least 1 month in bare metal and 12 months in drug elut-
ing stents. GP IIb/IIIa antagonists were used on discre-
tion of the operator.
Biochemical analyses
After 10 h overnight fasting, peripheral venous blood
specimens were obtained from participants via an ante-
cubital vein. Fasting plasma glucose (FPG) was measured
by a hexokinase enzyme method. HbA1c was measuredigibility (n=3964) 
Excluded (n=971) 
Not meeting inclusion criteria (n=869) 
Declined to participate (n=102) 
Non-diabetic patients (n=2228) 
Lost to follow-up (n=47)
Non-diabetic patients (n=2279) 
Lost to follow-up (n=51)
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analyzer (COBAS INTEGRA 400, Roche Diagnostics
GmbH, Mannheim, Germany). Total cholesterol, HDL-
cholesterol, and triglycerides levels were assessed using
enzyme-colorimetric tests; LDL cholesterol was esti-
mated based on Friedewald’s formula. LDL-cholesterol
was not calculated if the serum triglyceride level was
more than 400 mg/dl. Assay performance was monitored
every 50 tests, using the lipid control serum available
commercial kit. Baseline blood sampling (before cardiac
catheterization) for HbA1c repeated at 1 and 6 months
after procedure.
Study endpoints and definitions
Diabetes mellitus was defined as the fasting blood sugar
concentration ≥ 126 mg/dL, or the use of an oral
hypoglycemic agent or insulin at the time of admission.
The HbA1c levels before coronary stenting, and 1 and
6 months after the procedure was measured for diabetic
patients and the mean of the 3 measurements was con-
sidered for assessing the patients’ glycaemic control.
“Good-control group” was defined as diabetic patients
with mean HbA1c ≤ 7%, “poor-control group” was
defined as diabetic patients with mean HbA1c > 7%.
Procedural success was defined as Thrombolysis In
Myocardial Infarction Flow (TIMI) grade 3 with a re-
sidual stenosis < 10%. Myocardial infarction (MI) was
defined as the acute-onset chest pain and/or typical
modification on electrocardiogram (ST- or T-wave
modification or new left bundle branch block) and an
elevation of creatine kinase to> 3 times of the upper
reference limit. Target vessel revascularization (TVR)
was characterized by ischemia-driven percutaneous or
surgical revascularization of the treated vessel. Target le-
sion revascularization (TLR) by PCI was defined as treat-
ment of a lesion in the stent or within 5 mm of the stent
borders. The primary end point of the present study was
12-month cumulative MACE, defined as death, non-fatal
MI, and the need for TVR.
Patient follow-up
The data on the early outcomes and occurrence of
death, new non-fatal MI, need for CABG, subsequent
need for repeat PCI in all groups were recorded. Follow
up visits were scheduled at 1, 6, and 12 months after
procedure conducted by clinic visits or if the patients
did not attend clinics for the scheduled visits performed
by telephone interviews. For the telephone follow-up
interviews, at least five attempts were made to contact
participants or their first-degree relatives. If telephone
interviews were unsuccessful, the participants were con-
tacted by mail using their home address.
Of a total of 2993 patients compatible with our selec-
tion criteria, 55 (51 in non-diabetic group, 3 incontrolled group and 1 in uncontrolled group) patients
were lost at the 1-month and 54 (47 in non-diabetic
group, 4 in good-control group and 3 in poor-control
group) patients at the 6- month follow-up.
Revascularization of the target vessel was considered
to have been prompted by ischemia if there was evi-
dence of angina. If the patients did not have angina
symptoms, a functional stress test was performed within
12 months after the procedure to reveal silent ischemia.
Repeat cardiac catheterization was performed for recur-
rent symptoms or objective evidence of ischemia with
provocative testing. Routine angiographic follow-up was
not undertaken. One-year clinical follow-up rate was
96.1%.
Statistical analysis
The Kolmogorov-Smirnov test was applied to examine
normal distribution. Continuous variables are expressed
as mean ± SD and were compared among non-diabetic,
diabetic controlled, and diabetic uncontrolled groups by
analysis of variance (ANOVA) followed by Scheffe’s
post-hoc test for pairwise comparisons. Categorical vari-
ables were compared using a chi-square test, and were
presented as absolute frequencies with percentages.
Event-free survival curves were constructed using the
Kaplan-Meier method and compared using log-rank test.
Individuals were censored at the first cardiovascular
event. Cox multivariate analyses were used to determine
independent predictors of MACE. Variables were
entered into the model based on their statistical signifi-
cance in univariable analyses (entering criterion p ≤ 0.20)
as well as their clinical significance. To exclude the im-
pact of HbA1c level fluctuation during the follow-up
period and appropriately define the patients’ group, land-
mark analyses were performed at the landmark times of
1-month and 6-month [15]. For all analysis, the statis-
tical package SPSS version 15.0 for windows (SPSS Inc,
Chicago, Illinois, USA) was used. All p values were 2-
tailed with significance defined as p ≤ 0.05.
Results
Among 2884 patients (mean age ± SD, 57.7± 10.6 years;
70.1% men) who entered in the analysis for assessment of
the outcomes, 2181 (75.6%) were non-diabetic and 703
(24.4%) were diabetic. Of the 703 diabetic patients, 291
(41.4%) were controlled and 412 (58.6%) were uncon-
trolled. The baseline clinical and laboratory characteristics
of the study patients are presented in Table 1. Diabetic
patients were older and were less likely to be male as com-
pared to non-diabetics. The prevalence of current smok-
ing and statin-use was also lower in diabetic patients
compared with non-diabetic patients; however, patients
with diabetes had higher prevalence of hypertension,
hyperlipidemia, and ACEIs/ARBs consumption as well as




DM (n = 291)
Poor-control
DM (n = 412)
P-value* P-value† P-value{
Age (year) 57.4 ± 10.8 59.9 ± 9.9 58.0 ± 9.8 <0.0001 0.27 0.009
Male sex 1653 (75.8) 165 (56.7) 203 (49.3) <0.0001 <0.0001 0.07
Hypertension 1006 (46.1) 172 (59.1) 262 (63.6) <0.0001 <0.0001 0.35
Hyperlipidemia 1318 (61.5) 224 (77.8) 328 (79.6) <0.0001 <0.0001 0.58
Current smoking 1026 (47.0) 79 (27.1) 106 (25.7) <0.0001 <0.0001 0.86
Family history of CAD 502 (23.1) 63 (22.1) 89 (21.6) 0.77 0.45 0.78
BMI (kg/m2) 27.3 ± 4.25 28.3 ± 4.1 28.2 ± 4.5 <0.0001 < 0.0001 0.85
WC (cm) 99.4 ± 9.7 101.9 ± 9.0 102.3 ± 10.1 <0.0001 < 0.0001 0.61
EF< 30% 68 (4.3) 7 (3.5) 17 (5.9) 0.71 0.18 0.21
Medications
Insulin 0 (0) 17 (6.0) 69 (17.0) <0.0001 <0.0001 <0.0001
OHA 0 (0) 84 (28.9) 171 (41.5) <0.0001 <0.0001 0.001
ACEIs/ARBs 1295 (59.4) 180 (61.9) 288 (69.9) 0.35 <0.0001 0.04
Statins 1849 (84.8) 255 (87.6) 362 (87.9) 0.121 0.06 0.912
Beta-blockers 1915 (87.8) 244 (83.8) 355 (86.2) 0.11 0.55 0.34
Data are presented as mean ± SD or n (%).
* Non-diabetic patients versus good-control (diabetic patients with HbA1c≤ 7%).
† Non-diabetic patients versus poor-control (diabetic patients with HbA1c> 7%).
{ Good-control versus poor-control diabetic patients.
ACEIs, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor blockers; BMI, body mass index; CAD, coronary artery disease; DM, diabetes mellitus;
EF, ejection fraction; OHA, oral hypoglyceamic agent; WC, waist circumference.
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(WC). Diabetic patients with good glycaemic control were
older and less often female than uncontrolled diabetics,
and less commonly treated with insulin and ACEIs/ARBs.
As seen in Table 2, Diabetic patients showed higher
levels of TG and FBS. Diabetic controlled group as com-
pared to uncontrolled group had significantly lower
levels of TG and HbA1c.
The cardiac catheterization data of the study patients
are summarized in Table 3. Diabetic patients had higher
prevalence of 3-vessel disease and were more treated with




DM (n = 291)
P
(n
LDL-C (mmol/l) 2.52 ± 1.02 2.43 ± 0.92 2
HDL-C (mmol/l) 1.05 ± 0.28 1.05 ± 0.28 1
TCH (mmol/l) 4.38 ± 1.18 4.28 ± 1.16 4
TG (mmol/l) 1.90 ± 1.10 1.93 ± 1.09 2
FPG (mmol/l) 5.34 ± 0.68 7.07 ± 2.14 1
Mean HbA1c (%) - 6.6 ± 0.7 8
Cr (μmol/l) 100.8 ± 27.6 101.3 ± 60.8 9
Data are presented as mean ± SD.
* Non-diabetic patients versus good-control (diabetic patients with HbA1c≤ 7%).
† Non-diabetic patients versus poor-control (diabetic patients with HbA1c> 7%).
{ Good-control versus poor-control diabetic patients.
FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low
creatinine.between the diabetic and non-diabetic patients regarding
the rest of clinical, laboratory and cardiac catheterization
parameters. Also, no significant difference was observed
between diabetic controlled and uncontrolled with respect
to cardiac catheterization parameters.
During the 12-months follow-up in the entire popula-
tion, 95 (3.3%) MACEs comprised of 40 (1.4%) TVR, 36
(1.2%) non-fatal MI, and 19 (0.6%) cardiovascular mortal-
ity were indexed. Although there was significant difference
between the poor-controlled diabetic patients and non-
diabetics with respect to rate of TVR (3.2% vs. 1.1%, re-
spectively, p=0.002), the rate was similar in good-oor-control DM
=412)
P-value* P-value† P-value{
.51 ± 1.15 0.12 0.80 0.33
.08 ± 0.56 0.95 0.27 0.36
.50 ± 1.35 0.17 0.10 0.02
.15 ± 1.17 0.68 <0.0001 0.01
0.19 ± 3.89 <0.0001 < 0.0001 < 0.0001
.8 ± 1.3 – – < 0.0001
9.8 ± 32.5 0.88 0.58 0.68
-density lipoprotein cholesterol; TCH, total cholesterol; TG, triglycerides; Cr,








Type C lesion 1458 (66.9) 203 (69.8) 280 (68.0) 0.33 0.69 0.62
CTO 78 (3.6) 6 (2.1) 11 (2.7) 0.23 0.46 0.63
3-vessel disease 358 (16.8) 57 (20.2) 102 (25.1) 0.18 <0.0001 0.12
RVD< 3 mm 1092 (50.1) 165 (56.7) 236 (57.3) 0.04 0.006 0.88
SSL> 30 mm 896 (41.1) 128 (44.0) 174 (42.2) 0.35 0.66 0.70
CR 1312 (60.2) 164 (56.4) 213 (51.7) 0.21 0.001 0.22
Drug-eluting stent 1159 (54.6) 192 (67.1) 272 (66.8) <0.0001 <0.0001 0.86
Number of stents 1.3 ± 0.6 1.3 ± 0.6 1.3 ± 0.5 0.33 0.41 0.81
Data are presented as mean ± SD or n (%).
* Non-diabetic patients versus good-control (diabetic patients with HbA1c≤ 7%).
† Non-diabetic patients versus poor-control (diabetic patients with HbA1c> 7%).
{ Good-control versus poor-control diabetic patients.
CR, complete revascularization CTO, chronic total occlusion; RVD, reference vessel diameter; SSL, sum of the stents’ length.
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p= 0.54). There were no statistically significant differences
among the groups with respect to non-fatal MI, cardiovas-
cular mortality, in-hospital MACEs and total-MACEs
(Table 4). Figure 2 demonstrates freedom-from-MACE
survival curves in the three groups of non-diabetics, good-
controlled diabetics, and poor-controlled diabetics.
Table 5 presents uni- and multi-variable Cox regres-
sion analysis for predictors of MACE. After adjustment
for potential confounders, the risk of MACE in diabetic
uncontrolled patients (HbA1c> 7%) was 2.1 times of the
risk in non-diabetic patients (adjusted HR=2.09; 95%
CI, 1.10 to 3.95; p= 0.02). The confounders included age,
sex, hypertension, hyperlipidemia, current smoking,
waist circumference, insulin therapy, ACEIs/ARBs use,
statin use, 3-vessel disease, and complete revasculariza-
tion. However, the risk of MACE in diabetic patients





Total MACE 65 (3.0) 9 (3.1)
In-hospital MACE 27 (1.2) 3 (1.0)
TVR 23 (1.1) 4 (1.4)
TLR 9 (0.4) 3 (1.0)
CABG 10 (0.4) 0 (0)
Non-fatal MI 26 (1.1) 4 (1.4)
All-cause mortality 25 (1.1) 1 (0.3)
Cardiac death 16 (0.7) 1 (0.3)
Non-cardiac death 9 (0.4) 0 (0)
Data are presented as n (%).
* Non-diabetic patients versus good-control (diabetic patients with HbA1c≤ 7%).
† Non-diabetic patients versus poor-control (diabetic patients with HbA1c> 7%).
{ Good-control versus poor-control diabetic patients.
CABG, coronary artery bypass grafting surgery; MACE, major adverse cardiovascular eve
revascularization.significantly different from that of non-diabetic patients
(adjusted HR= 1.48; 95% CI, 0.68 to 3.21; p= 0.32).
Figure 3 shows freedom from MACE curves in the three
groups after adjustment for potential confounders.
We defined the patients’ group based on the average
of 3-times measurements of HbA1c levels, before PCI
and 1 and 6 months after PCI. However, a total of 11
diabetic patients were lost to follow-up by 6 months of
follow-up. Furthermore, HbA1c level fluctuated around
7.0% over time leading to crossing over between good-
control and poor-control group classifications. In order
to exclude the impact of HbA1c level fluctuation around
7.0% during the follow-up period and appropriately de-
fine the patients’ group, we employed 1-month and 6-
month landmark analyses to examine the association of
post-procedural glycemic control and 1-year clinical
MACE of diabetic patients undergoing PCI at the land-
mark times. The results are summarized in Table 6.Poor-control DM
(n = 412)
P-value* P-value† P-value{
21 (5.1) 0.85 0.09 0.33
3 (0.7) 1.00 0.79 0.70
13 (3.2) 0.55 0.002 0.14
4 (1.0) 0.16 0.13 1.00
6 (1.4) 0.62 0.03 0.04
6 (1.4) 0.77 0.62 1.00
4 (1.0) 0.35 1.00 0.41
2 (0.5) 0.71 1.00 1.00
2 (0.5) 0.61 0.69 0.51
nts; MI, myocardial infarction; TLR, target lesion revascularization; TVR, target vessel
Figure 2 Kaplan-Meier event-free survival curves for freedom
of MACE in the 3 groups of non-diabetic patients, diabetics
with good control (mean HbA1c≤ 7%) and diabetics with poor
control (mean HbA1c>7%).
Kassaian et al. Cardiovascular Diabetology 2012, 11:82 Page 6 of 10
http://www.cardiab.com/content/11/1/82Discussion
In-stent restenosis (ISR) is mainly caused by the effects of
vascular smooth muscle cell proliferation (neointimal
hyperplasia) and migration. As part of mechanical injury
response, immediately after stent placement, endotheliumTable 5 Cox regression analysis for predictors of major adver
Univariable analysis
Crude HR 95% CI
Age (year) 1.01 0.99 to 1.03
Male sex 1.14 0.72 to 1.83
Hypertension 1.02 0.68 to 1.53
Hyperlipidemia 0.86 0.56 to 1.31
Current smoking 0.65 0.42 to 1.00
Waist circumference 0.98 0.95 to1.00
Insulin 1.82 0.74 to 4.47
ACEIs/ARBs use 1.12 0.73 to 1.70
Statin use 0.91 0.52 to 1.62
3-vessel disease 1.35 0.83 to 2.20
Drug-eluting stent 0.68 0.45 to 1.03
CR 0.63 0.41 to 0.96
Group
Non-Diabetics 1* –
Good-control diabetics 1 1.06 0.53 to 2.12
Poor-control diabetics 2 1.59 0.96 to 2.67
* Reference category.
ACEIs, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor blocke
complete revascularization.
1 Diabetic patient with HbA1c≤ 7%.
2 Diabetic patient with HbA1c> 7%.damage and the deposition of a layer of platelets and fibrin
occur at the site of injury [16]. ISR also occurs lately over
several months at the location around stent struts by a
chronic inflammatory phase. Neointima increases up to
three months after stenting, with little change to six
months, and a gradual decrease thereafter [17]. Thus, the
time frame of first 6 months after stent implantation was
used in this study as follow-up to look at glycemic control.
An “exaggerated” vascular proliferation is observed in
patients with diabetes mellitus. In diabetic animals, hyper-
insulinemia rather than hyperglycemia per se, appears to
be important in determining the exaggerated neointimal
hyperplasia after balloon angioplasty [18]. In order to as-
sess this topic in human, we analyzed for the effect of the
post-procedural glycaemic control in the first six months
after PCI on occurrence of MACE.
The main finding of our study was that glyceamic con-
trol to be significantly associated with 1-year outcome in
diabetic patients undergoing elective PCI with stent im-
plantation. We observed that diabetics with poor gly-
caemic control are at 2.1 times more risk of developing
MACE while good-controlled diabetics showed rates of
adverse clinical events comparable to those of non-
diabetic patients. The higher MACE rate in the poor-
control group was mostly driven by a higher rate of TVR.
Our findings are in agreement with several previous
studies reporting increased rates of MACE following PCIse cardiovascular events at 12 months
Multivariable analysis
P Adjusted HR 95% CI P
0.15 1.01 0.98 to1.03 0.53
0.57 1.80 0.96 to 3.38 0.07
0.92 0.99 0.60 to 1.65 0.98
0.48 0.99 0.59 to 1.65 0.97
0.06 0.60 0.35 to 1.03 0.07
0.04 0.97 0.95 to 1.00 0.03
0.19 1.09 0.32 to 3.73 0.89
0.61 0.97 0.59 to 1.59 0.44
0.76 0.81 0.42 to 1.56 0.53
0.23 1.15 0.61 to 2.12 0.67
0.07 0.54 0.33 to 0.87 0.01
0.03 0.75 0.43 to 1.29 0.30
– 1* – –
0.88 1.48 0.68 to 3.21 0.32
0.07 2.09 1.10 to 3.95 0.02
rs; CI, confidence interval; HR, hazard ratio; WC, waist circumference; CR,
Table 6 Multivariable Cox regression model for detecting
the independent effect of post-procedural diabetic
control on major adverse cardiovascular events (MACE)
at 12 months







1.54 0.74 to 3.19 0.250
Poor-control diabetics 2
(n = 412)







2.02 0.80 to 5.09 0.136
Poor-control diabetics 2
(n = 402)







1.40 0.60 to 7.90 0.236
Poor-control diabetics 2
(n = 430)
4.10 1.04 to 7.81 0.043
*Reference group.
1 Diabetic patient with HbA1c≤ 7%.
2 Diabetic patient with HbA1c> 7%.
Figure 3 Cox-adjusted event-free survival curves for freedom of MACE in the 3 groups after adjustment for potential confounders
including age, sex, hypertension, hyperlipidemia, current smoking, waist circumference, insulin therapy, ACEIs/ARBs use, statin use,
and 3-vessel disease.
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two previous investigators [19, 20] examined the effect of
glycaemic control on need for TVR in diabetic patients
undergoing elective PCI. They observed lower rates of
TVR, cardiac rehospitalization and recurrent angina in
optimally-controlled (HbA1c≤ 7%) diabetic patients. com-
parable rates of adverse events in optimally-controlled dia-
betics and non-diabetics were also observed. A historical
cohort study on 206 diabetic patients with drug-eluting
stent implantation showed that pre-procedural HbA1c
level is an independent predictor of MACE [21]. It is also
demonstrated that a HbA1c concentration of 6% to 7% is
associated with a significantly higher risk of MACEs,
TVR, and cardiovascular mortality following elective PCI
in nondiabetic patients [24].
However, conflicting findings exist on the impacts of
intensive glucose control with aggressive HbA1c goals
on cardiovascular events [25-27]. In a 2-year follow-up
study [28], the incidence of cardiovascular events was
statistically similarly increased after acute myocardial in-
farction (AMI) in known diabetics and newly diagnosed
diabetics compared with non-diabetic patients including
IGT patients. However, when baseline characteristics
were compared between the two groups, the level of
HbA1c of newly diagnosed diabetics was significantly
lower than that of known diabetic group (5.7 ± 0.4 mg/
dL vs. 8.1 ± 1.5 mg/dL, p< 0.05). There are several previ-
ously published studies reporting that pre-procedural
HbA1c levels are not predictive of cardiovascular events
in diabetic patients following successful PCI [29-33].
In a recently published study on 952 diabetic patients
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lationship was observed between pre-procedural HbA1c
levels and patients’ outcome[33]. The investigators attrib-
uted such conflicting finding, at least in part, to high rate
of drug-eluting stent use in their study (70%). The use of
drug-eluting stent in our study (about 66% in diabetic
patients and 53% in non-diabetics) was similar to that
study [33]; however, we observed that pre- and post-
procedural glycaemic control predicts MACE following
PCI even after adjustment for potential confounding effect
of drug-eluting stent implantation.
Observational data relating uncontrolled diabetes to
higher rates of cardiovascular events in this group of
patients encouraged the researchers to assess the effect
of therapies that improve glycemic control on cardiovas-
cular risk. Clinical trials have already demonstrated that
therapies that improve glycemic control decrease the
risk of microvascular disease, including retinopathy,
nephropathy, and neuropathy [34]. However, trials
attempting to decrease macrovascular events have been
unsuccessful; in the Action to Control Cardiovascular
Risk in Diabetes (ACCORD) [35], Action in Diabetes
and Vascular Disease: Preterax and Diamicron Modified
Release Controlled Evaluation (ADVANCE) [36], and
Veterans Affairs Diabetes Trial (VADT) studies [37],
improved glycemic control showed no reduction in the
rate of cardiovascular events and in ACCORD trial [35],
even it was associated with increased risks of death from
any cause and death from cardiovascular events.
Ike and colleagues [38] have recently published a study
on the effect of glycaemic control after PCI in patients
with pre-procedural uncontrolled diabetes (HbA1c≥ 6.9)
and observed that glycemic control started at PCI and
continued afterwards for approximately 300 days was not
associated with improved clinical MACE at follow-up.
The authors suggested that a so-called “metabolic memory
(legacy) effect” which is a complex of MACE-increasing
factors due to chronic hyperglycaemia might have ad-
versely affected the clinical outcome in all diabetic
patients with pre- procedural impaired glycaemic control
irrespective of their post-procedural glycaemic control.
However, this study was not a prospective cohort study
and one cannot exclude the possibility that the clinical
outcome may have been influenced for this reason.
The higher rates of MACE in diabetic patients with
worse glycaemic control may have several explanations:
There is evidence that chronic hyperglycemia induces vas-
cular endothelial cell damage, with resultant vasomotor
dysfunction, excessive extracellular matrix formation, and
increased cellular proliferation. Hyperinsulinemia has been
widely proposed as a predisposing factor for stent resten-
osis in diabetic patients [39], and concerns have been
raised over the management of diabetes with exogenously
administered insulin, as it may accelerate progression ofCAD through its atherogenic mechanisms [40, 41]. Cur-
rently data regarding the impact of insulin therapy on re-
stenosis after PCI are controversial [42-44]. While Abizaid
et al. [45] found an increased rate of TLR in insulin-treated
diabetic patients compared with non-diabetic patients,
others [46, 47] demonstrated no significant difference in
restenosis rates between the two groups. In our study there
was no difference between the insulin-treated and non-
insulin-treated diabetics with respect to TVR and MACE,
and in multivariate Cox regression analysis insulin usage
was not an independent predictor for MACE.
The novel aspect of our study was that in addition to
pre-procedural HbA1c levels, we measured the post-
procedural circulating HbA1c concentrations at 1 and
6 months after PCI. Hence, it not only reflects the ambi-
ent glycaemic control 2–3 months before procedure, but
also surrogates the post-procedural glycaemic control in
the first six months after PCI.
It is also notable that in this study we observed that
current cigarette smoking and WC were tended to be pre-
dictors for better PCI outcome. Current smoking showed
a protective effect on outcome of PCI in univariable ana-
lysis but it was not found to be an independent predictor
for outcome after controlling for other covariates
(Adjusted HR: 0.60, 95% CI: 0.35 to 1.03, p = 0.07). Waist
circumference however showed statistically significant and
independent protective effect on outcome of PCI in multi-
variable model. Although we don’t know the exact reason
of such observation in our study, there is conflicting data
regarding the effect of obesity on outcome of PCI [48],
and a more optimal medical treatment in the obese group
could explain the observed better outcome (“obesity para-
dox”) in these patients [49].Limitations
There are several potential limitations in our study that
needs to be mentioned. First, in this study routine angio-
graphic follow-up was not performed, and thus absolute
restenosis rates could not be reported. Second, this was
a single-center experience and larger multi-center stud-
ies should confirm our findings. Finally, although our
method of assessment, protocol for calibrating HbA1c
levels, and guidelines of reporting ensures high accuracy,
HbA1c measurement error might be still a concern es-
pecially because this index was not derived from
repeated measurements over time.Conclusions
In conclusion, these data suggest that good glycaemic
control to obtain HbA1c levels ≤7% in diabetic patients
undergoing coronary artery stenting may be beneficial in
reducing the risk of restenosis and in improvement of
the clinical outcome after PCI at 1-year follow-up.
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